James Rooney, MD
Internal Medicine · Metairie, LANPI 1588638464
Payments from drug & device makers
Across 486 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$8K
- AbbVie$1K
- Amgen$957
- AstraZeneca$768
- Lilly USA, LLC$694
- Novo Nordisk$661
- plus $3K from 27 others
Across 1 payment — averaging $6242.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6K
What the payments were for
- Food & beverage$7,40397%
- Education$1973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $8,059 |
| AbbVie(2 entities) | 74 | $1,104 |
| Amgen(2 entities) | 54 | $957 |
| AstraZeneca | 43 | $768 |
| Lilly USA, LLC | 45 | $694 |
| Novo Nordisk | 56 | $661 |
| Johnson & Johnson | 34 | $484 |
| Pfizer | 35 | $445 |
| Merck | 21 | $328 |
| Almatica Pharma LLC | 14 | $291 |
| Astellas Pharma US Inc | 7 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $272 |
| Radius Health, Inc. | 9 | $176 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $169 |
| Kowa Pharmaceuticals America, Inc. | 7 | $144 |
| Bayer | 7 | $116 |
| Novartis | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 6 | $91 |
| Shire North American Group Inc | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Acerus Pharmaceuticals Corporation | 3 | $52 |
| Eisai Inc. | 3 | $46 |
| Abbott | 2 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| GSK | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Dexcom, Inc. | 1 | $14 |
| Edwards Lifesciences | 1 | $14 |
| Alcon | 1 | $14 |
| Boston Scientific | 1 | $13 |
How this compares
$15,659 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 105 | $116,120 |
| EliquisApixaban | 99 | $91,117 |
| ProliaDenosumab | 27 | $45,960 |
| OzempicSemaglutide | 35 | $38,468 |
| Repatha SureclickEvolocumab | 59 | $36,185 |
| RybelsusSemaglutide | 25 | $33,435 |
| JardianceEmpagliflozin | 41 | $32,021 |
| XareltoRivaroxaban | 18 | $28,230 |
| JanuviaSitagliptin Phosphate | 23 | $27,720 |
| UbrelvyUbrogepant | 17 | $25,673 |
| MyrbetriqMirabegron | 22 | $14,765 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $14,460 |
| FarxigaDapagliflozin Propanediol | 15 | $13,978 |
| TrulicityDulaglutide | 12 | $13,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $694 | $129,271117 claims |
| PfizerEliquis | $445 | $91,11799 claims |
| Novo NordiskOzempic, Rybelsus | $661 | $71,90360 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi | $20 | $50,08375 claims |
| AmgenProlia | $957 | $45,96027 claims |
| AbbVieUbrelvy, Synthroid | $1,104 | $30,98194 claims |
| Johnson & JohnsonXarelto | $484 | $28,23018 claims |
| MerckJanuvia | $328 | $27,72023 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $20 | $24,12639 claims |
| AstraZenecaFarxiga, Symbicort | $768 | $19,81529 claims |
| Astellas Pharma US IncMyrbetriq | $276 | $14,76522 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $53 | $11,97911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Metairie
- Robert JeanfreauMetairie$13.4M
- Frederick DantagnanMetairie$421K
- William SmithNew Orleans$50.5M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.